Trial Profile

A Modular Phase I/IIa, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 08 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Saruparib (Primary) ; Torvutatug samrotecan (Primary) ; Bevacizumab; Carboplatin
Indications Adenocarcinoma; Lung cancer; Ovarian cancer; Solid tumours
Focus Adverse reactions; First in man
Acronyms FONTANA
Sponsors AstraZeneca

28 Aug 2025 Planned number of patients changed from 446 to 506.
29 Jun 2025 Given protocol has been amended as above-1) Number of treatment arms has been changed from 4 to 5. 2) Planned number of patients has been changed from 396 to 446.
29 Jun 2025 Planned number of patients changed from 396 to 446.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com